← Back to results
NCT07034222PHASE4ACTIVE_NOT_RECRUITING

12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

A 12-month Single-arm Real-world Study to Determine the Safety and Efficacy of Lecanemab in Patients With Early Alzheimer's Disease

Sponsor: Ruijin Hospital

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Request endpoint coverage

Key Facts

Study type
INTERVENTIONAL
Conditions
Alzheimer's Disease(AD)
Interventions
Administer Leqemi 10 mg/kg, every two weeks.
Enrollment
80 participants
Primary completion
Jan 2026
Study completion
Jan 2026
First posted
Jun 2025
Last updated
Jun 2025

Primary Endpoints (CT.gov)

Change in Amyloid Burden as Assessed by Aβ-PET Standardized Uptake Value Ratio (SUVR)

Time frame: Baseline, 6 months, 12 months

Change in Amyloid Burden as Assessed by Centiloid Scale

Time frame: Baseline, 6 months, 12 months

Secondary Endpoints

Incidence of treatment-emergent adverse events (TEAEs)

Change in Cognitive Function as Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

Change in Cognitive Function as Assessed by Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14)

Eligibility Criteria

Inclusion Criteria: * Meets the NIA-AA 2011 diagnostic criteria for: Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) or Mild Alzheimer's Disease Dementia. -Confirmed Aβ pathology by: Aβ-PET scan or CSF Aβ42/Aβ40 ratio (results within 6 months prior to screening). -Cognitive scales (within 3 months): Clinical Dementia Rating (CDR) global score 0.5-1 and/or Mini-Mental State Examination (MMSE) score 20-30. * APOE genotype results available. * MRI/SWI eligibility: * No exclusionary findings (see Exclusion Criteria for details). * Laboratory tests within normal ranges or deemed non-clinically significant by the investigator: Routine tests: Liver/kidney function, CBC, urinalysis, fecal occult blood. Thyroid function: Free T3, free T4, TSH. Vitamin B12 (and methylmalonic acid \[MMA\], if available). Coagulation panel: PT/INR, aPTT (required). Negative for syphilis, HIV, or other infections that may affect cognition. Exclusion Criteria: \- MRI/SWI exclusionary findings:

Read full criteria on CT.gov →

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Request coverage →

Source

Open on ClinicalTrials.gov